Citius Pharmaceuticals, Inc. is a biopharmaceutical company focused on the development and commercialization of first-in-class critical care products, with a pipeline of anti-infectives in oncology, adjunct cancer care, stem cell therapy and prescription products. The Company's FDA approved LYMPHIR candidate is a targeted immunotherapy for an initial indication in the treatment of cutaneous T-cell lymphoma. Its late-stage pipeline also includes Mino-Lok, and CITI-002 (Halo-Lido). Mino-Lok is an antibiotic lock solution used to treat patients with catheter-related bloodstream infections (CRBSIs) and central line associated bloodstream infections (CLABSIs). Halo-Lido is a topical formulation of halobetasol propionate, a corticosteroid, and lidocaine that is intended for the treatment of hemorrhoids. The Company is also seeking to develop and commercialize the NoveCite mesenchymal stem cells (NC-iMSCs) to treat acute respiratory conditions with a near term focus on ARDS.
äŒæ¥ã³ãŒãCTXR
äŒç€ŸåCitius Pharmaceuticals Inc
äžå Žæ¥Aug 03, 2017
æé«çµå¶è²¬ä»»è
ãCEOãMazur (Leonard L)
åŸæ¥å¡æ°23
蚌åžçš®é¡Ordinary Share
æ±ºç®ææ«Aug 03
æ¬ç€Ÿæåšå°11 Commerce Dr Fl 1
éœåžCRANFORD
蚌åžååŒæNASDAQ OMX - NASDAQ BASIC
åœUnited States of America
éµäŸ¿çªå·07016-3501
é»è©±çªå·19089676677
ãŠã§ããµã€ãhttps://www.citiuspharma.com/
äŒæ¥ã³ãŒãCTXR
äžå Žæ¥Aug 03, 2017
æé«çµå¶è²¬ä»»è
ãCEOãMazur (Leonard L)